Weichen Bo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weichen Bo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Jiankun Hu
Sichuan University
2 shared publicationsLinyu Yang
Sichuan University
2 shared publications- Na Li
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publications Peng Bai
Sichuan University
2 shared publications- Peng Wang
Sichuan University
2 shared publications Quan Yuan
Sichuan University
2 shared publications
Latest Publications
- 4 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18051-18075
Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6 H -pyrano[4,3- c ]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors
Developing highly selective PARP1 inhibitors is a promising strategy to improve the therapeutic window compared with dual PARP1/2 inhibitors. Through structure-guided design and optimization, we developed (R)-A17, a novel, highly selective PARP1 inhibitor featuring a unique tricyclic scaffold. It demonstrates nanomolar enzymatic potency (PARP1 IC50 = 2.4 nM), exceptional 65.8-fold selectivity over PARP2, and robust antiproliferative activity in BRCA-deficient cells. (R)-A17 exhibits favorable pharmacokinetic properties with complete oral bioavailability (F = 100%) in mice. Mechanistically, it selectively inhibits PARP1-mediated PARylation and induces DNA damage and G2/M phase arrest. In vivo, oral administration of (R)-A17 produced dose-dependent antitumor efficacy in BRCA mutant xenograft models, achieving tumor growth inhibition values of 57.8, 86.3, and 91.3% at doses of 0.3, 1, and 3 mg/kg, respectively, while also synergizing effectively with liposomal irinotecan in an HCT116 xenograft model. These results establish (R)-A17 as a promising candidate and validate the design strategy for the next-generation PARP1-targeted therapy.
- 4 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18051-18075
Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6 H -pyrano[4,3- c ]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors
Developing highly selective PARP1 inhibitors is a promising strategy to improve the therapeutic window compared with dual PARP1/2 inhibitors. Through structure-guided design and optimization, we developed (R)-A17, a novel, highly selective PARP1 inhibitor featuring a unique tricyclic scaffold. It demonstrates nanomolar enzymatic potency (PARP1 IC50 = 2.4 nM), exceptional 65.8-fold selectivity over PARP2, and robust antiproliferative activity in BRCA-deficient cells. (R)-A17 exhibits favorable pharmacokinetic properties with complete oral bioavailability (F = 100%) in mice. Mechanistically, it selectively inhibits PARP1-mediated PARylation and induces DNA damage and G2/M phase arrest. In vivo, oral administration of (R)-A17 produced dose-dependent antitumor efficacy in BRCA mutant xenograft models, achieving tumor growth inhibition values of 57.8, 86.3, and 91.3% at doses of 0.3, 1, and 3 mg/kg, respectively, while also synergizing effectively with liposomal irinotecan in an HCT116 xenograft model. These results establish (R)-A17 as a promising candidate and validate the design strategy for the next-generation PARP1-targeted therapy.
- 7 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 12346-12377
Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven Cancers
In this study, we describe a series of pyridone derivatives as pan-MEK/RAF nondegrading molecular glues. Through investigation of the metabolic sites of the reported MEK/RAF inhibitor 16b, rational design and systematic SAR studies led to the discovery of compound D56, which exhibits well-balanced in vitro and in vivo potency. D56 could effectively block MEK and ERK phosphorylation with IC50 values of 0.379 and 0.015 nM, respectively. Furthermore, protein-protein interaction (PPI) assays demonstrated that D56 induces MEK1-BRAF and MEK1-CRAF complexes formation at low concentrations, indicating that D56 is a potent MEK/RAF molecular glue. D56 possesses an excellent selectivity over other 332 human-related kinases at 1 μM. Most importantly, in AsPC-1, HCT116, and OCI-AML-3 mouse xenograft models, D56 achieved significant tumor growth inhibition. Taken together, these findings suggest that compound D56 is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
- 7 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 12346-12377
Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven Cancers
In this study, we describe a series of pyridone derivatives as pan-MEK/RAF nondegrading molecular glues. Through investigation of the metabolic sites of the reported MEK/RAF inhibitor 16b, rational design and systematic SAR studies led to the discovery of compound D56, which exhibits well-balanced in vitro and in vivo potency. D56 could effectively block MEK and ERK phosphorylation with IC50 values of 0.379 and 0.015 nM, respectively. Furthermore, protein-protein interaction (PPI) assays demonstrated that D56 induces MEK1-BRAF and MEK1-CRAF complexes formation at low concentrations, indicating that D56 is a potent MEK/RAF molecular glue. D56 possesses an excellent selectivity over other 332 human-related kinases at 1 μM. Most importantly, in AsPC-1, HCT116, and OCI-AML-3 mouse xenograft models, D56 achieved significant tumor growth inhibition. Taken together, these findings suggest that compound D56 is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
- 31 December 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (1) , 122-137
DRPMKB1.0: A Comprehensive Knowledge Base for an AI-Oriented Drug Repositioning Prediction Model
Drug repositioning (DR) reduces the risks and costs of drug development by identifying new uses for approved drugs. The rapid growth of artificial intelligence (AI) has led to many computational models. However, without effective integration, excess models can waste resources and obscure valuable ones. While large language models (LLMs) are preferred for their broad applicability, integrating them with a personalized knowledge base improves task-specific accuracy. Thus, we developed the AI-oriented drug repositioning prediction model knowledge base (DRPMKB 1.0). This knowledge base compiles data from PubMed up to March 2024, covering two interfaces (display and interaction) and four dimensions (data, model, application, and reference). It includes 45 categories, 193 models, and 693 data entries, offering a comprehensive data sharing platform for DR. DRPMKB 1.0 establishes a dual-evaluation framework to standardize model selection, appraising both inherent model quality and the evidentiary support for its predictions. DRPMKB 1.0 integrates diverse data and models for personalized DR, offering tailored model recommendations based on user data, improving prediction accuracy. DRPMKB 1.0 also offers a foundation for developers to integrate models and data sets seamlessly. The knowledge base supports AI enhancement through a knowledge base for continuous model refinement.
- 31 December 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (1) , 122-137
DRPMKB1.0: A Comprehensive Knowledge Base for an AI-Oriented Drug Repositioning Prediction Model
Drug repositioning (DR) reduces the risks and costs of drug development by identifying new uses for approved drugs. The rapid growth of artificial intelligence (AI) has led to many computational models. However, without effective integration, excess models can waste resources and obscure valuable ones. While large language models (LLMs) are preferred for their broad applicability, integrating them with a personalized knowledge base improves task-specific accuracy. Thus, we developed the AI-oriented drug repositioning prediction model knowledge base (DRPMKB 1.0). This knowledge base compiles data from PubMed up to March 2024, covering two interfaces (display and interaction) and four dimensions (data, model, application, and reference). It includes 45 categories, 193 models, and 693 data entries, offering a comprehensive data sharing platform for DR. DRPMKB 1.0 establishes a dual-evaluation framework to standardize model selection, appraising both inherent model quality and the evidentiary support for its predictions. DRPMKB 1.0 integrates diverse data and models for personalized DR, offering tailored model recommendations based on user data, improving prediction accuracy. DRPMKB 1.0 also offers a foundation for developers to integrate models and data sets seamlessly. The knowledge base supports AI enhancement through a knowledge base for continuous model refinement.